Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 3618692 | HLA-DR (HLA-DR) | endometrial carcinoma | NA | NA | NA | only_studied | |
| to elucidate the relationship between endometrial carcinoma and the constitution, hla antigen typing (a-locus, 13; b-locus, 20; c-locus, 6; dr-locus, 9) was investigated in 74 patients with endometrial carcinoma. | |||||||
| 3618692 | HLA-DRB1*08 | endometrial carcinoma | NA | NA | NA | positive+negation | |
| a significant increase in two hla antigens, cw7 and drw8, was demonstrated, but there was no intimate correlation between cw7 or drw8 and the three complications commonly associated with endometrial carcinoma--diabetes mellitus, obesity, and hypertensive disease. | |||||||
| 3618692 | HLA-C*07 | endometrial carcinoma | NA | NA | NA | positive+negation | |
| a significant increase in two hla antigens, cw7 and drw8, was demonstrated, but there was no intimate correlation between cw7 or drw8 and the three complications commonly associated with endometrial carcinoma--diabetes mellitus, obesity, and hypertensive disease. | |||||||
| 3618692 | HLA-DRB1*08 | endometrial carcinoma | NA | NA | NA | unclassified | |
| on the basis of these results, a new classification of endometrial carcinoma was proposed as follows: type a is positive cw7 or drw8 group; type b is negative for cw7 and drw8 and positive for the complications mentioned; type c is negative for cw7 and drw8, negative for the complications mentioned, and positive for dr 5; type d is a non-a, non-b, and non-c type. | |||||||
| 3618692 | HLA-C*07 | endometrial carcinoma | NA | NA | NA | unclassified | |
| on the basis of these results, a new classification of endometrial carcinoma was proposed as follows: type a is positive cw7 or drw8 group; type b is negative for cw7 and drw8 and positive for the complications mentioned; type c is negative for cw7 and drw8, negative for the complications mentioned, and positive for dr 5; type d is a non-a, non-b, and non-c type. | |||||||
| 8473417 | HLA-DR (HLA-DR) | endometrial carcinoma | NA | NA | NA | unclassified | |
| spheroids reminiscent of endometrial glands were formed by allowing three-dimensional aggregation of endometrial epithelial cells of a cloned hla-dr negative endometrial carcinoma cell line (ecc1) over agarose. | |||||||
| 30474304 | HLA-A*01 | endometrial carcinoma | NA | NA | NA | unclassified | |
| trb-j1 usage, in combination with the hla-a*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: comparisons with microscopic assessments of lymphocyte infiltrates. | |||||||
| 3670729 | HLA-DR (HLA-DR) | senile plaque | NA | choline | NA | unclassified | |
| using immunohistochemical procedures with two specific monoclonal antibodies to hla-dr, hla-dr-positive reactive microglia were found in gray matter throughout the cortex of postmortem brains of patients with senile dementia of the alzheimer type (sdat) and were particularly concentrated in the areas of senile plaque formation. | |||||||
| 12527224 | HLA-A*02 | acute disease | NA | hepatitis | NA | unclassified | |
| although the immune response is quite diverse and numerous epitopes can be targeted, we observe that, especially during acute disease, one epitope (ns3 1073-81) is commonly recognised in hla-a2 positive individuals. | |||||||
| 15230855 | HLA-CLASS II (HLA CLASS II) | acute disease | NA | hepatitis | NA | unclassified | |
| antiviral cd4(+) t cell responses have been shown to accompany resolution of acute disease and there is also a consistent association between hla class ii genes, notably hladrb1*1101 (and the closely linked hladqb1*0301) and disease resolution. | |||||||
Copyright 2024